Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Exclusion Criteria

• •1. Patients who had adjuvant or neoadjuvant therapy for non-metastatic disease given within the last 12 months.
• •2. Patients who had received Oxaliplatin within 12 months prior to diagnosis of metastatic disease.
• •3. Patients on concurrent anti cancer therapy other than that allowed in the study.
• •4. Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids
• •5. Presence of clinically apparent or suspected brain metastasis.
• •6. Patients who have had myocardial infarction, severe congestive heart failure, or significant arrhythmia within the past 6 months.
• •7. Serious active infection at the time of pre-study screening.
• •8. Active or history of autoimmune disorders/conditions.
• •9. Women who are pregnant or lactating
• •10. Concurrent active malignancy.
• •11. Ascites, pleural effusions, or osteoblastic bone metastases as the only site of disease.
• •12. Other prior malignancies, except for cured or adequately treated malignancies for which there has been no evidence of activity for more than 5 years.
• •13. Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
• •14. Patients with history of life threatening allergic reactions to food or drugs
• •15. Patients with symptomatic peripheral neuropathy\> Grade 1.
• •16. Known positive HIV, Hepatitis B surface antigen or Hepatitis C antibody.